» Articles » PMID: 38532786

Weak Base Drug-induced Endolysosome Iron Dyshomeostasis Controls the Generation of Reactive Oxygen Species, Mitochondrial Depolarization, and Cytotoxicity

Overview
Date 2024 Mar 27
PMID 38532786
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Approximately 75 % of marketed drugs have the physicochemical property of being weak bases. Weak-base drugs with relatively high pK values enter acidic organelles including endosomes and lysosomes (endolysosomes), reside in and de-acidify endolysosomes, and induce cytotoxicity. Divalent cations within endolysosomes, including iron, are released upon endolysosome de-acidification. Endolysosomes are "master regulators of iron homeostasis", and neurodegeneration is linked to ferrous iron (Fe)-induced reactive oxygen species (ROS) generation via Fenton chemistry. Because endolysosome de-acidification-induced lysosome-stress responses release endolysosome Fe, it was crucial to determine the mechanisms by which a functionally and structurally diverse group of weak base drugs including atropine, azithromycin, fluoxetine, metoprolol, and tamoxifen influence endolysosomes and cause cell death.

Methods: Using U87MG astrocytoma and SH-SY5Y neuroblastoma cells, we conducted concentration-response relationships for 5 weak-base drugs to determine EC values. From these curves, we chose pharmacologically and therapeutically relevant concentrations to determine if weak-base drugs induced lysosome-stress responses by de-acidifying endolysosomes, releasing endolysosome Fe in sufficient levels to increase cytosolic and mitochondria Fe and ROS levels and cell death.

Results: Atropine (anticholinergic), azithromycin (antibiotic), fluoxetine (antidepressant), metoprolol (beta-adrenergic), and tamoxifen (anti-estrogen) at pharmacologically and therapeutically relevant concentrations (1) de-acidified endolysosomes, (2) decreased Fe levels in endolysosomes, (3) increased Fe and ROS levels in cytosol and mitochondria, (4) induced mitochondrial membrane potential depolarization, and (5) increased cell death; effects prevented by the endocytosed iron-chelator deferoxamine.

Conclusions: Weak-base pharmaceuticals induce lysosome-stress responses that may affect their safety profiles; a better understanding of weak-base drugs on Fe interorganellar signaling may improve pharmacotherapeutics.

References
1.
Funk R, Krise J . Cationic amphiphilic drugs cause a marked expansion of apparent lysosomal volume: implications for an intracellular distribution-based drug interaction. Mol Pharm. 2012; 9(5):1384-95. PMC: 3348458. DOI: 10.1021/mp200641e. View

2.
Jannuzzi G, Gatti G, Magni P, Spina E, Pacifici R, Zuccaro P . Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response. Ther Drug Monit. 2002; 24(5):616-27. DOI: 10.1097/00007691-200210000-00006. View

3.
Nujic K, Banjanac M, Munic V, Polancec D, Erakovic Haber V . Impairment of lysosomal functions by azithromycin and chloroquine contributes to anti-inflammatory phenotype. Cell Immunol. 2012; 279(1):78-86. DOI: 10.1016/j.cellimm.2012.09.007. View

4.
Tian C, Wen Q, Fan T . Cytotoxicity of atropine to human corneal epithelial cells by inducing cell cycle arrest and mitochondrion-dependent apoptosis. Exp Toxicol Pathol. 2015; 67(10):517-24. DOI: 10.1016/j.etp.2015.07.006. View

5.
Neil-Dwyer G, Bartlett J, Mcainsh J, Cruickshank J . Beta-adrenoceptor blockers and the blood-brian barrier. Br J Clin Pharmacol. 1981; 11(6):549-53. PMC: 1402194. DOI: 10.1111/j.1365-2125.1981.tb01169.x. View